BeOne Medicines (BEIGF) Current Assets (2015 - 2026)

BeOne Medicines (BEIGF) has reported Current Assets for 12 consecutive years, with $7.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets rose 67.41% year-over-year to $7.2 billion in Q2 2026; TTM through Jun 2026 was $7.2 billion, a 67.41% increase from a year earlier, with the FY2025 full-year figure at $6.2 billion, up 56.17% from the prior year.
• Current Assets was $7.2 billion for Q2 2026 at BeOne Medicines, up from $6.6 billion in the prior quarter.
• Over five years, Current Assets peaked at $7.2 billion in Q2 2026 and troughed at $3.8 billion in Q2 2024.
• A 5-year average of $5.1 billion and a median of $4.6 billion in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 32.29% in 2023 and soared 69.42% in 2026, its largest moves.
• Over 5 years, Current Assets stood at $5.2 billion in 2022, then slipped by 19.27% to $4.2 billion in 2023, then decreased by 5.04% to $4.0 billion in 2024, then soared by 56.17% to $6.2 billion in 2025, then increased by 15.76% to $7.2 billion in 2026.
• The last three Current Assets figures came in at $7.2 billion (Q2 2026), $6.6 billion (Q1 2026), and $6.2 billion (Q4 2025), per Business Quant data.